Not all prostate cancers are the same. Therefore, not all prostate cancer treatment plans should be the same either. It is important to identify those patients who need more aggressive versus less aggressive prostate cancer treatment. Unfortunately, traditional markers are unable to fully differentiate between aggressive and non-aggressive cancers. Which often leads to over-treatment of patients.
Luckily, Prolaris provides unique additional information about a patient’s prognosis and may be used with other clinical factors in helping the healthcare provider make treatment recommendations. In addition, it is can help determine more appropriate treatment plans for individual patients. By providing personal risk assessment, Prolaris can accurately measure the aggressiveness of an individuals prostate cancer. In doing so, it can help protect against over-treatment.
If you have less aggressive prostate cancer, otherwise known as slow-growing prostate cancer, your doctor may suggest active surveillance as a potential treatment option. With active surveillance, your doctor will monitor you frequently (such as every 3 to 6 months) with different tests and sometimes biopsies.
Find out more information about how knowing the aggressiveness of your prostate cancer could change your treatment options.